^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN-001

    i
    Other names: GEN-001, LR20011, GEN 001, GEN001, LR-20011, LR 20011
    Associations

    News

    Trials
    Company:
    Genome & Company, LG Chem
    Drug class:
    T-cell stimulant, Dendritic cell activator, IL-15 stimulant, IL-7 agonist
    Related drugs:
    Associations

    News

    Trials
    1year
    Phase II study of GEN-001 in combination with avelumab in patients with PD-L1–positive locally advanced, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who have progressed after second-line (2L) and beyond (GEN001-201 study). (ASCO-GI 2024)
    Treatment of patients with GC/GEJC with GEN-001 in combination with avelumab in the ≥ 3L setting showed promising antitumor activities with an overall manageable safety profile. The results from this trial will be updated about its effects on clinical outcome, including survival, safety, and biomarker findings. Clinical trial information: NCT05419362.
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    1year
    GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Genome & Company | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    1year
    GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=148, Recruiting, Genome & Company | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • GEN-001
    over1year
    GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, Genome & Company | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    over2years
    GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Genome & Company
    New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    3years
    Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Korean Cancer Study Group
    Clinical • New trial
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    GEN-001